BR112014019166A2 - promotores para expressão aumentada de proteína em meningococos - Google Patents
promotores para expressão aumentada de proteína em meningococosInfo
- Publication number
- BR112014019166A2 BR112014019166A2 BR112014019166A BR112014019166A BR112014019166A2 BR 112014019166 A2 BR112014019166 A2 BR 112014019166A2 BR 112014019166 A BR112014019166 A BR 112014019166A BR 112014019166 A BR112014019166 A BR 112014019166A BR 112014019166 A2 BR112014019166 A2 BR 112014019166A2
- Authority
- BR
- Brazil
- Prior art keywords
- promoters
- meningococci
- protein expression
- increased protein
- rna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/60—Vectors containing traps for, e.g. exons, promoters
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
resumo “promotores para expressão aumentada de proteína em meningococos” são descritos novos promotores destinados a conduzir transcrição em meningococos, e.g., com o objetivo de superexpressão de antígenos protéicos para retenção em vesículas da membrana. há deficiência de promotores pora modificados na sequência poli-g do tipo selvagem que podem causar variação de fase. genes que codificam rrna meningocócico (e.g., para rna de 16s) podem ser usados para conduzir transcrição de um gene que codifica proteína. esses procedimentos podem ser usados em combinação.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261594159P | 2012-02-02 | 2012-02-02 | |
PCT/EP2013/052108 WO2013113917A1 (en) | 2012-02-02 | 2013-02-01 | Promoters for increased protein expression in meningococcus |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014019166A2 true BR112014019166A2 (pt) | 2017-07-04 |
Family
ID=47683718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014019166A BR112014019166A2 (pt) | 2012-02-02 | 2013-02-01 | promotores para expressão aumentada de proteína em meningococos |
Country Status (11)
Country | Link |
---|---|
US (1) | US9657297B2 (pt) |
EP (2) | EP3299467B1 (pt) |
JP (2) | JP5957541B2 (pt) |
CN (1) | CN104114706A (pt) |
AU (1) | AU2013214105A1 (pt) |
BR (1) | BR112014019166A2 (pt) |
CA (1) | CA2861946A1 (pt) |
ES (1) | ES2654613T3 (pt) |
MX (1) | MX2014008988A (pt) |
RU (1) | RU2014135522A (pt) |
WO (1) | WO2013113917A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS61246B1 (sr) | 2014-02-28 | 2021-01-29 | Glaxosmithkline Biologicals Sa | Modifikovani meningokokni fhbp polipeptidi |
EP3607967A1 (en) | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
CN109485704B (zh) * | 2018-11-27 | 2022-04-19 | 温州大学 | 一种脑膜炎球菌fHbp蛋白的表达系统 |
CN111321141B (zh) * | 2018-12-14 | 2021-02-26 | 上海凯赛生物技术股份有限公司 | 稳定期特异性启动子及其应用 |
CN111850003A (zh) * | 2020-07-09 | 2020-10-30 | 华中农业大学 | 一种重组表达的多杀性巴氏杆菌硫胺素周质结合蛋白及应用 |
CN114854701B (zh) * | 2022-03-16 | 2023-09-22 | 福建福大百特生物科技有限公司 | 一种微泡菌超氧化物歧化酶及其编码基因 |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
US4551433A (en) | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
US5698438A (en) | 1994-10-18 | 1997-12-16 | Oregon Health Sciences University | Bacterial hemoglobin receptor gene |
IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
US6180111B1 (en) | 1995-05-18 | 2001-01-30 | University Of Maryland | Vaccine delivery system |
DK0991761T3 (da) | 1997-08-21 | 2008-05-19 | Nederlanden Staat | Hidtil ukendte mutaner af gramnegative mucosale bakterier og anvendelse deraf i vacciner |
US6645503B1 (en) | 1998-03-10 | 2003-11-11 | Wyeth Holdings Corporation | Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria |
EP2261355A3 (en) | 1998-05-01 | 2012-01-11 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
GB9818004D0 (en) | 1998-08-18 | 1998-10-14 | Smithkline Beecham Biolog | Novel compounds |
GB9820003D0 (en) | 1998-09-14 | 1998-11-04 | Smithkline Beecham Biolog | Novel compounds |
CA2347849C (en) | 1998-10-22 | 2013-06-25 | The University Of Montana | Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof |
GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
DK1127137T4 (da) | 1998-11-03 | 2014-02-10 | Nederlanden Staat | LPS med reduceret toksicitet fra genetisk modificerede gram-negative bakterier |
GB9826886D0 (en) | 1998-12-07 | 1999-01-27 | Smithkline Beecham Biolog | Novel compounds |
AU1580300A (en) | 1998-12-08 | 2000-06-26 | Smithkline Beecham Biologicals (Sa) | Novel compounds |
WO2000042191A2 (en) | 1999-01-15 | 2000-07-20 | Smithkline Beecham Biologicals S.A. | Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
JP2004537954A (ja) | 1999-01-15 | 2004-12-24 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ナイセリア・メニンギティディス・ポリペプチドbasb052 |
EP1144643A1 (en) | 1999-01-15 | 2001-10-17 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Neisseria meningitidis antigen |
EP1147194A1 (en) | 1999-01-22 | 2001-10-24 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
JP2004537955A (ja) | 1999-01-22 | 2004-12-24 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ナイセリア・メニンギティディス由来のbasb055ポリヌクレオチド及びポリペプチド、その使用 |
CA2360667A1 (en) | 1999-01-22 | 2000-07-27 | Smithkline Beecham Biologicals S.A. | Neisseria meningitidis basb054 polypeptides and encoding polynucleotides and uses thereof |
GB9902084D0 (en) | 1999-01-29 | 1999-03-24 | Smithkline Beecham Biolog | Novel compounds |
GB9902070D0 (en) | 1999-01-29 | 1999-03-24 | Smithkline Beecham Biolog | Novel compounds |
GB9902937D0 (en) | 1999-02-10 | 1999-03-31 | Smithkline Beecham Biolog | Novel compounds |
DK1163343T3 (da) | 1999-03-12 | 2010-04-19 | Glaxosmithkline Biolog Sa | Neisseria meningitidis antigene polypeptider, tilsvarende polynukleotider og beskyttende antistoffer |
DK1228217T3 (da) | 1999-04-30 | 2013-02-25 | Novartis Vaccines & Diagnostic | Konserverede neisseria-antigener |
CN102580072A (zh) * | 1999-05-19 | 2012-07-18 | 诺华疫苗和诊断有限公司 | 组合式奈瑟球菌组合物 |
GB9918206D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Novel compounds |
GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
US6531131B1 (en) | 1999-08-10 | 2003-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for Neisseria meningitidis |
GB9925559D0 (en) | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
AU1917501A (en) | 1999-11-12 | 2001-06-06 | University Of Iowa Research Foundation, The | Control of neisserial membrane synthesis |
ATE460484T1 (de) | 1999-11-29 | 2010-03-15 | Novartis Vaccines & Diagnostic | 85 kda antigen von neisseria |
US7947291B2 (en) | 2000-01-25 | 2011-05-24 | The University Of Queensland | Modified surface antigen |
NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
US6936261B2 (en) | 2000-07-27 | 2005-08-30 | Children's Hospital & Research Center At Oakland | Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
GB0109289D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Novel compounds |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0213622D0 (en) | 2002-06-13 | 2002-07-24 | Glaxosmithkline Biolog Sa | Vaccine Corporation |
PL399492A1 (pl) | 2002-08-02 | 2012-11-19 | Glaxosmithkline Biologicals S.A. | Szczepionka |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
CA2550927A1 (en) | 2003-12-23 | 2005-07-14 | Glaxosmithkline Biologicals S.A. | A gram negative bacterium with reduced lps level in the outer membrane and use thereof for treating gram negative bacterial infection |
GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
US9034345B2 (en) | 2005-01-27 | 2015-05-19 | Children's Hospital & Research Center Oakland | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
US9931397B2 (en) | 2005-06-27 | 2018-04-03 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
CN101378778B (zh) | 2005-12-22 | 2013-02-06 | 葛兰素史密丝克莱恩生物有限公司 | 肺炎球菌多糖缀合物疫苗 |
EP2041236A1 (en) | 2006-06-26 | 2009-04-01 | Bp Exploration Operating Company Limited | Wellbore fluid |
EP2185576A4 (en) | 2007-08-02 | 2011-01-12 | Childrens Hosp & Res Ct Oak | FHBP- AND LPXL1-BASED VESICIUM VACCINES FOR BROADBAND PROTECTION AGAINST NEISSERIA MENINGITIDIS-RELATED DISEASES |
US9579372B2 (en) | 2008-02-21 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Meningococcal fHBP polypeptides |
EP2631245A1 (en) | 2008-03-10 | 2013-08-28 | Children's Hospital & Research Center at Oakland | Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use |
RU2477145C2 (ru) * | 2008-05-30 | 2013-03-10 | ДЗЕ Ю.Эс.Эй., ЭС РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТАРИ ОФ ДЗЕ АРМИ, ОН БЕХАФ ОФ УОЛТЕР РИД АРМИ | Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения |
GB0816447D0 (en) | 2008-09-08 | 2008-10-15 | Glaxosmithkline Biolog Sa | Vaccine |
GB0819633D0 (en) | 2008-10-25 | 2008-12-03 | Isis Innovation | Composition |
AU2009329193A1 (en) | 2008-12-17 | 2011-07-14 | Novartis Ag | Meningococcal vaccines including hemoglobin receptor |
BRPI1013902A2 (pt) | 2009-04-30 | 2019-09-24 | Children´S Hospital & Res Center At Oakland | proteínas de ligação de fator quimérico h(fhbp) é método de uso |
GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
BR112012024348B1 (pt) | 2010-03-30 | 2022-11-08 | Children's Hospital & Research Center At Oakland | Composição imunogênica, seu uso, proteína de ligação ao fator h de ocorrência não natural, e célula bacteriana geneticamente modificada |
CA2846290A1 (en) | 2011-08-31 | 2013-03-07 | Children's Hospital & Research Center Oakland | Engineered sequences to facilitate expression of antigens in neisseria and methods of use |
-
2013
- 2013-02-01 US US14/375,222 patent/US9657297B2/en active Active
- 2013-02-01 EP EP17199436.1A patent/EP3299467B1/en active Active
- 2013-02-01 RU RU2014135522A patent/RU2014135522A/ru not_active Application Discontinuation
- 2013-02-01 BR BR112014019166A patent/BR112014019166A2/pt not_active IP Right Cessation
- 2013-02-01 JP JP2014555238A patent/JP5957541B2/ja not_active Expired - Fee Related
- 2013-02-01 AU AU2013214105A patent/AU2013214105A1/en not_active Abandoned
- 2013-02-01 WO PCT/EP2013/052108 patent/WO2013113917A1/en active Application Filing
- 2013-02-01 ES ES13703562.2T patent/ES2654613T3/es active Active
- 2013-02-01 EP EP13703562.2A patent/EP2809785B1/en active Active
- 2013-02-01 CN CN201380007752.4A patent/CN104114706A/zh active Pending
- 2013-02-01 CA CA2861946A patent/CA2861946A1/en not_active Abandoned
- 2013-02-01 MX MX2014008988A patent/MX2014008988A/es unknown
-
2016
- 2016-02-22 JP JP2016030838A patent/JP2016093202A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN104114706A (zh) | 2014-10-22 |
RU2014135522A (ru) | 2016-03-27 |
WO2013113917A1 (en) | 2013-08-08 |
JP2016093202A (ja) | 2016-05-26 |
JP2015506693A (ja) | 2015-03-05 |
EP3299467A2 (en) | 2018-03-28 |
EP2809785B1 (en) | 2017-11-01 |
EP3299467B1 (en) | 2021-08-11 |
US20150218566A1 (en) | 2015-08-06 |
CA2861946A1 (en) | 2013-08-08 |
MX2014008988A (es) | 2014-08-27 |
ES2654613T3 (es) | 2018-02-14 |
JP5957541B2 (ja) | 2016-07-27 |
AU2013214105A1 (en) | 2014-07-24 |
US9657297B2 (en) | 2017-05-23 |
EP2809785A1 (en) | 2014-12-10 |
EP3299467A3 (en) | 2018-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014019166A2 (pt) | promotores para expressão aumentada de proteína em meningococos | |
BR112014019116A8 (pt) | Kit, moléculas de anticorpo, composição farmacêutica, métodos de tratamento, usos, vetor, célula hospedeira e método de produção de uma molécula de anticorpo | |
BR112014018916A2 (pt) | classe de genes de resistência a glifosato | |
ECSP14004829A (es) | Moléculas de unión para bcma y cd3 | |
BR112013031262A2 (pt) | "exotoxinas a de pseudomonas com menos epítopos imunogênicos de célula b e t, e seu uso no tratamento e prevenção de câncer, bem como molécula quimérica, ácido nucleico, vetor de expressão, células, composição farmacêutica e métodos para inibir crescimento de célula-alvo e de produção de endotoxinas a de pseudomonas e de molécula quimérica". | |
BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
BR112012006912A8 (pt) | Hipervesiculação de cepas de shigella | |
BR112014019901A8 (pt) | Proteínas de fator viii recombinante | |
BRPI0817299A8 (pt) | vacinas e componentes de vacina para inibição de células microbianas | |
UY35456A (es) | Moléculas de unión para bcma y cd3 | |
BR112013029834A2 (pt) | vacinas individualizadas para câncer | |
AR072531A1 (es) | SENAL DE POLIADENILACIoN | |
BR112016015936A2 (pt) | Combinação imunogênica, molécula de ácido nucleico, vetor, célula hospedeira, método de produção recombinante dos antígenos e composição | |
GB201020995D0 (en) | Biological materials and uses thereof | |
CL2012003054A1 (es) | Anticuerpos contra la angiopoyetina 2 humana (ang-2); composicion farmaceutica que contiene dicho anticuerpo; uso del anticuerpo para preparar medicamento destinado a la prevencion de metastasis; acido nucleico que codifica dicho anticuerpo; vector de expresión. | |
BR112016019735A2 (pt) | fhbp, polipeptídeo, plasmídeo ou outro ácido nucleico, célula hospedeira, vesículas de membrana, e, composição imunogênica | |
BR112014024282A2 (pt) | anticorpos ligantes ao receptor b1 da bradicinina | |
BR112015000585A8 (pt) | método para preparar uma cepa mutante de mycoplasma hyopneumoniae, vetores, cepa mutante, vacina, kit de vacinação e usos do vetor e da cepa mutante | |
MX2019007248A (es) | Enzimas de polimerizacion para reacciones de secuenciacion. | |
BR112017013576A2 (pt) | produção melhorada de lipídios de núcleo em leveduras oleaginosas | |
BR112015006223A2 (pt) | unidade de tratamento de água subaquática e método para limpar a dita unidade | |
BR112015003947A2 (pt) | proteínas de fusão e métodos para tratar, prevenir ou melhorar dor | |
WO2013177593A3 (en) | Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies | |
AR092630A1 (es) | Metodos y composiciones para prevenir la incorporacion erronea de norleucina en proteinas | |
BR112015022495A2 (pt) | promotores de feijão-soja constitutivos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |